Bayer more stringent in glyphosate settlement talks due to downturn

“The company will consider a deal only if it is financially reasonable and puts in place a mechanism to resolve potential future claims efficiently,” Chief Executive Werner Baumann said
Read Article

German drugs and pesticides company Bayer said the economic downturn has prompted it to take a tougher stance in talks to settle claims its glyphosate-based weedkillers cause cancer, even as its earnings rose.

The pandemic has significantly slowed the mediation process, it said in a statement.

“The company will consider a deal only if it is financially reasonable and puts in place a mechanism to resolve potential future claims efficiently,” Chief Executive Werner Baumann said.

“This applies now more than ever,” he added, citing a looming recession and considerable liquidity challenges as a result of the coronavirus pandemic.

The number of U.S. plaintiffs blaming its glyphosate-based weedkillers for their cancer reached 52,500, up from 48,600 in February, the company added.

Bayer denies that claims Roundup – or its active ingredient glyphosate – cause cancer, saying decades of independent studies have shown it to be safe for human use.

The company added that first-quarter adjusted earnings before interest, taxes, depreciation and amortisation (EBITDA) rose 10.2 per cent to 4.39 billion euros ($4.76 billion), surpassing average analyst expectations of 4.17 billion, according to Refinitiv data.

The beat was driven by a 14 per cent gain in earnings at the agriculture division from higher sales of crop chemicals and corn seeds. Earnings were further underpinned by a 19 per cent increase in revenue from stroke prevention drug Xarelto.

Bayer warned, however, that it was unable to assess the impact of the pandemic on group earnings this year.

BayerCoronavirus pandemicXarelto
Comments (0)
Add Comment